Press release
Plasma-Derived Therapeutics Market (2025) | Plasma-Derived Therapies, Plasma Fractionation, IVIG Demand, Plasma Collection, Albumin & Rare Disease Treatment Growth, Plasma-Based Drug Expansion
Plasma-Derived Therapeutics Market Size 2026
plasma-derived therapeutics market was valued at US$ 20.16 Billion in 2023. The market size reached US$ 21.26 Billion in 2024 and is expected to reach US$ 35.10 Billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033.
Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/plasma-derived-therapeutics-market?kb
United States: Recent Industry Developments
✅ March 2026: CSL Behring expanded plasma fractionation capacity in the U.S. to strengthen supply of immunoglobulins and albumin amid rising global demand.
✅ February 2026: Grifols enhanced its plasma collection network across North America, improving donor center efficiency and scaling immunotherapy production.
✅ January 2026: Takeda (BioLife Plasma Services) advanced automation in plasma donation centers to optimize yield and improve operational throughput for plasma-derived medicines.
✅ December 2025: Octapharma USA increased investment in plasma protein purification technologies to support growth in rare disease and bleeding disorder therapies.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/plasma-derived-therapeutics-market?kb
List of Key Players 2026:
Takeda Pharmaceutical Company Limited, Johnson and Johnson (DePuy Synthes), Octapharma AG, Arthrex, Inc., Grifols, S.A., ADMA Biologics, Inc., CSL, Evolve Biologics Inc., Kamada Pharmaceuticals, and Bio Products Laboratory Ltd
Key Strategic Growth Forecast Projections 2026:
The Global Plasma-Derived Therapeutics Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
✅ May 2026: Global leaders including Grifols, CSL Limited, and Takeda Pharmaceutical expanded plasma collection and fractionation capacity to strengthen supply chains amid rising demand for immunoglobulin and specialty plasma therapies.
✅ April 2026: Companies including CSL Behring and Grifols advanced large-scale investment programs focused on plasma center expansion and manufacturing upgrades to improve yield efficiency and reduce therapy shortages.
✅ March 2026: CSL Limited continued its multi-billion-dollar capacity expansion strategy, strengthening vertically integrated plasma collection networks and increasing fractionation output to support immunology and rare disease therapies.
✅ February 2026: Strategic collaborations accelerated, including partnerships involving CSL and biotech innovators to develop next-generation plasma-derived and recombinant hybrid therapies for immunology and bleeding disorders.
✅ January 2026: Takeda Pharmaceutical and Octapharma enhanced production flexibility across immunoglobulin and albumin portfolios through facility modernization and advanced purification technologies.
✅ December 2025: Grifols strengthened its global plasma value chain through regulatory approvals and capacity expansion initiatives, improving access to plasma-derived medicines across international markets.
✅ October 2025: Industry players including Kedrion Biopharma and ADMA Biologics focused on plasma center expansion and supply chain integration to secure long-term raw plasma sourcing and reduce dependency risks.
How Our Market Research Process Works:
The global Plasma-Derived Therapeutics Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Plasma-Derived Therapeutics adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• Jan 2026 - GSK acquires RAPT Therapeutics ($2.2B), strengthening its immunology pipeline with a long-acting anti-IgE antibody asset relevant to allergy and autoimmune diseases
• Jan 2026 - Eli Lilly completes acquisition of Ventyx Biosciences ($1.2B), adding NLRP3 and inflammation-targeted immunology programs to its mid-stage pipeline
• Jan 2026 - BioCryst Pharmaceuticals completes acquisition of Astria Therapeutics, expanding its hereditary angioedema franchise and adding late-stage plasma kallikrein inhibitor navenibart
• Jan 2026 - Amgen acquires Dark Blue Therapeutics ($840M), boosting its oncology pipeline with small-molecule protein degrader programs
• Jan 2026 - Illumina acquires SomaLogic ($425M + royalties), expanding proteomics and data-driven precision medicine capabilities relevant to biopharma discovery platforms
• Jan 2026 - Halozyme acquires Surf Bio ($400M), enhancing its subcutaneous drug delivery and injectable biologics platform technology
• Jan 2026 - Haemonetics acquires Vivasure Medical (€185M), adding vascular closure and cardiovascular procedural technologies tied to biologic treatment support systems
• Jan 2026 - OpenAI acquires Torch Health ($60M), expanding AI applications in healthcare workflows and clinical data systems
Request Strategic Market Customization: https://datamintelligence.com/customize/plasma-derived-therapeutics-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical strengthened its plasma-derived therapy manufacturing capabilities, focusing on immunoglobulin and albumin production for domestic and export markets.
✅ February 2026: KM Biologics expanded production capacity for plasma fractionation products supporting hemophilia and immune deficiency treatments.
✅ January 2026: Japanese Red Cross Blood Center enhanced plasma collection and processing systems to improve availability of plasma-derived medicinal products.
✅ December 2025: Mitsubishi Tanabe Pharma advanced R&D in next-generation plasma protein therapies targeting rare and chronic diseases.
Major Segments Opportunity 2026:
By Product Type: Protein, Coagulation Factors, Others
By Application: Hemophilia, Idiopathic Thrombocytopenic Purpura (ITP), Primary Immunodeficiencies, Others
By End-User: Hospitals & Specialty Clinics, Ambulatory Surgical Centers, Homecare Services, Others
Regional Growth Intelligence for Market:
⇥ North America: 42% - Leads the global market due to strong plasma collection infrastructure, high treatment adoption, and advanced biologics manufacturing capacity.
⇥ Europe: 25% - Supported by established plasma fractionation facilities, increasing rare disease awareness, and strong healthcare reimbursement systems.
⇥ Asia-Pacific: 20% - Fastest-growing region driven by expanding healthcare access, rising diagnosis rates, and increasing investments in plasma collection networks.
⇥ Middle East & Africa: 8% - Gradual growth supported by improving healthcare infrastructure and increasing availability of specialty biologics.
⇥ South America: 5% - Emerging market with rising access to plasma-based therapies and improving healthcare systems.
Market Growth Drivers 2026:
Advancements in plasma fractionation technologies are improving yield efficiency, product purity, and scalability of immunoglobulins, albumin, and clotting factors.
Expansion of plasma collection centers and donor programs is strengthening global supply chains and reducing dependency risks.
Increasing development of next-generation immunoglobulin therapies, including high-concentration and subcutaneous formulations, is enhancing patient convenience and compliance.
Growing investments in recombinant and hybrid plasma-derived technologies are improving safety profiles and reducing pathogen transmission risks.
Rising strategic collaborations, mergers, and acquisitions among plasma manufacturers are consolidating market presence and expanding geographic reach.
Continuous innovation in viral inactivation and pathogen reduction technologies is improving product safety standards and regulatory compliance.
Expanding therapeutic applications of plasma-derived products into neurology, immunology, and critical care are creating new high-value growth opportunities.
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=plasma-derived-therapeutics-market?kb
FAQ
Q1: What is the present market size of the Plasma-Derived Therapeutics Market?
A: The Plasma-Derived Therapeutics Market was valued at US$ XX in 2025 and is projected to reach US$ XX by 2035, growing steadily over the forecast period.
Q2: How fast is the market expected to grow?
A: The Plasma-Derived Therapeutics market is expected to register a strong CAGR of % during the 2026-2032
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plasma-Derived Therapeutics Market (2025) | Plasma-Derived Therapies, Plasma Fractionation, IVIG Demand, Plasma Collection, Albumin & Rare Disease Treatment Growth, Plasma-Based Drug Expansion here
News-ID: 4511964 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Short-Range Air Surveillance Radar Market to Reach USD 9.56 Billion by 2035 | No …
The global short-range air surveillance radar market was valued at USD 6.42 billion in 2025 and is projected to reach USD 9.56 billion by 2035, growing at a CAGR of 6.5% during the forecast period from 2026 to 2035. The market is witnessing steady growth driven by increasing defense modernization programs, rising concerns over border security, and the growing need for real-time airspace monitoring capabilities. Short-range air surveillance radars play…
Air Ambulance Market to Reach USD 48.90 Billion by 2033 | North America Holds 46 …
The global air ambulance market was valued at USD 18.28 billion in 2025 and is projected to reach USD 48.90 billion by 2033, growing at a CAGR of 10.2% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by the increasing demand for rapid emergency medical transportation, rising incidence of trauma cases, cardiovascular emergencies, and critical care requirements worldwide. Air ambulance services play a…
Healthcare Robotics Systems Market to Reach USD 72.11 Billion by 2035 | North Am …
The global healthcare robotics systems market was valued at USD 14.53 billion in 2025 and is projected to reach USD 72.11 billion by 2035, growing at a CAGR of 17.39% during the forecast period from 2026 to 2035. The market is experiencing robust growth driven by the increasing adoption of robotic technologies across surgical procedures, rehabilitation therapies, hospital logistics, pharmacy automation, and patient care support applications. Healthcare providers are increasingly…
Agricultural Drone Market to Reach USD 50.07 Billion by 2033 | Asia Pacific Hold …
The global agricultural drone market was valued at USD 4.03 billion in 2025 and is projected to reach USD 50.07 billion by 2033, growing at a CAGR of 37.01% during the forecast period from 2026 to 2033. The market is witnessing exceptional growth driven by the increasing adoption of precision agriculture, rising demand for efficient crop monitoring solutions, and growing emphasis on improving agricultural productivity. Agricultural drones are becoming essential…
More Releases for Therapeutics
Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.
DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years.
DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,…
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611
Focused on growth…
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.
Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hodgkin's…
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.
Key Takeaways from…
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant…
